ArticleAmerican journal of medical genetics. Part A2025
Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants.
Article in American journal of medical genetics. Part A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trajectory of skill acquisition, loss, and regain in females with classic Rett syndrome.Journal of neurodevelopmental disorders · 2026Article
- Trajectory of skill acquisition, loss, and regain in females with classic Rett syndrome.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Rett syndrome (RTT) is a rare neurodevelopmental disorder typically caused by loss-of-function variants in the transcriptional regulator methyl-CpG binding protein-2 (MECP2) gene. These variants were historically believed to be incompatible with life in males; however, recent advances in genetic testing have revealed significant clinical heterogeneity. The current study aimed to improve our understanding of diagnostic experiences in males with confirmed pathogenic alteration of MECP2. An international sample of caregivers completed a survey of diagnostic experiences (N = 47) and phenomenological interviews (n = 32). Median [interquartile range; IQR] age of genetic diagnosis was 3 years [1.08, 6.75]. Multivariate analysis showed that for every year increase in year of birth, age of diagnosis (in years) decreased by 0.31. Qualitative findings demonstrate that medical biases and widespread misconceptions contribute to delays in accurate clinical diagnosis, which negatively impacts child health and family functioning. As genetic testing becomes more widely available, age of genetic diagnosis is decreasing, resulting in more providers and families with unexpected results and a notable lack of male-specific anticipatory guidance and clinical recommendations. Diagnostic providers must increase their awareness of males with confirmed pathogenic alterations of MECP2 and be prepared to deliver the diagnosis with empathy and accurate, up-to-date information on prognosis and treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.